Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

CA BOTANA International, Inc.

US Class II Ongoing · initiated 2025-10-10

CGMP Deviations

Safecor Health, LLC

US Class II Ongoing · initiated 2025-10-10

Labeling: Not Elsewhere Classified:Incorrect RFID tag labels applied to product by repackaging firm.

Atlantiscan

Canada Type I Ongoing · initiated 2025-10-10

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

Amerisource Health Services LLC

US Class II Ongoing · initiated 2025-10-09

CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that …

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

STAQ Pharma, Inc.

US Class III Ongoing · initiated 2025-10-09

Labeling: Incorrect or Missing Lot and/or Exp Date

ibspot

US Class II Ongoing · initiated 2025-10-09

Marketed Without an Approved NDA/ANDA

USV Private Limited

US Class II Ongoing · initiated 2025-10-09

Failed Impurities/Degradation Specifications: The result for 'Any individual unspecified impurity' exceeds the specification limit.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2025-10-09

CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

ASTRAZENECA PHARMACEUTICALS

US Class II Ongoing · initiated 2025-10-08

Lack of Assurance of Sterility:

Mohamed Hagar

US Class I Ongoing · initiated 2025-10-08

Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).

Sandoz Lisinopril HCT 20/25mg

Canada Type II Ongoing · initiated 2025-10-08

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2025-10-07

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) inst…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2025-10-07

CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit fo…